Global Health Solutions, INC 8-K filings

Turn Therapeutics announced positive interim Phase 2 data for GX-03 in atopic dermatitis, leading to an expanded trial population, and appointed former FDA Commissioner Dr. Stephen Hahn to a key role.

Turn Therapeutics Inc. provided an investor presentation detailing advancements in its GX-03 drug candidate for inflammatory diseases, including upcoming clinical trial milestones and market potential.

Turn Therapeutics announced an updated Stage 2 design for its Phase 2 program of GX-03 in atopic dermatitis, incorporating interim analysis data to broaden patient evaluation across all disease severities.

Turn Therapeutics presented updated investor information highlighting positive interim results for its GX-03 drug candidate in treating moderate-to-severe Atopic Dermatitis and advancing its Onychomycosis program.

Turn Therapeutics announced positive interim findings from its Phase 2 GX-03 trial for atopic dermatitis, showing high efficacy and a favorable safety profile, leading to trial optimization.

Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment detailing the efficacy of GX-03 in a murine dermatitis model.

Turn Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference on June 4, 2026, providing an update on its clinical-stage biotechnology.

Turn Therapeutics Inc. has appointed Dr. Stephen M. Hahn, former FDA Commissioner, as Executive Clinical and Regulatory Lead to guide the development of GX-03 for atopic dermatitis.

Turn Therapeutics announced its first quarter 2026 financial results, highlighting progress in its Phase 2 trial for GX-03 and securing $7 million in growth capital from Avenue Capital Group.

Turn Therapeutics reported full-year 2025 financial results, secured $25 million in growth capital, and announced progress on its Phase 2 GX-03 trial.

Turn Therapeutics announced a growth capital loan facility of up to $25 million from Avenue Capital Group to extend its operational runway and advance key dermatology programs.

Turn Therapeutics announced the appointment of Dr. Robert Redfield, former CDC Director, as Senior Advisor of Health Policy and Regulatory Affairs to guide GX-03 development.

Turn Therapeutics Inc. announced upcoming presentations at two major healthcare conferences to provide updates on its dermatology pipeline, including the Phase 2 clinical trial for GX-03 in atopic dermatitis.

Turn Therapeutics announced key corporate, pipeline, and financial updates, including clinical trial progress and a new board appointment, ahead of the J.P. Morgan Healthcare Conference.

Turn Therapeutics strengthens its board with the appointment of Martin Dewhurst, a seasoned life sciences and M&A expert, signaling a strategic focus on pipeline expansion and value creation.

Turn Therapeutics announced its third quarter 2025 financial results, highlighted by its NASDAQ listing, new board appointments, and a significant global agreement with Medline.

Turn Therapeutics announced its GX-03 technology was recognized for atopic dermatitis treatment and its CEO discussed healthcare communication with former CDC Director Dr. Robert Redfield.

Turn Therapeutics Inc. announced the appointment of Andrew Scott as Vice President of Corporate Communications to enhance investor relations and capital markets strategy.

Turn Therapeutics has entered a global supply, development, and license agreement with Medline, a leading medical-surgical product manufacturer, to commercialize products leveraging its PermaFusion delivery platform.

Turn Therapeutics Inc. has entered into a multi-year Global Supply, Development, and License Agreement with Medline Industries, LP for its proprietary PermaFusion delivery platform.

Turn Therapeutics provides a shareholder update highlighting continued execution across clinical and strategic milestones, including progress in its Phase 2 eczema trial and flexible financing strategy.

Turn Therapeutics Inc. announced the effectiveness of its S-1 registration for a direct listing on Nasdaq, alongside new executive employment agreements, corporate governance updates, and shareholder agreements.